AMGEN, INC. for AMGEN INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 20, 2022 | $2,410,000 | Replaced |
| 4th Quarter - Amendment (this page) | Jul 20, 2022 | $2,410,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Biosimilars reimbursement issues, no specific bill H.R. 3, Prescription drug pricing issues FDA issues, no specific bill Supply Chain Issues, no specific bill Patent thickets/product hopping, no specific bill Mergers/acquisitions, no specific bill H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 5260 Reduced Costs and Continued Cures Act H.R.5376, "Build Back Better Act Issues related to clinical trial diversity
| Lobbyist | Covered position, as disclosed |
|---|---|
| VICTORIA BLATTER | — |
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE New | Senator Debbie Stabeow (D-MI), left 2011, Legislative Director |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Medicare/Medicaid MMM
S. 99 The Medicare Drug Price Negotiation Act, issues related to international reference pricing and Part D redesign H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act, issues related to international reference pricing and Part D redesign S. 1943 and H.R. 3517, Issues related to DXA, osteoporosis Issues related to international reference pricing Issues related to the 340B program, no specific bill Reimbursement for biologics/biosimilars Issues related to Medicare Part D redesign Issues related to patient affordability issues, including copay cards, copay accumulators, National Benefit Payment Parameters ESRD bundle, calcimimetic access, no specific bill H.R. 19 Lower Costs, More Cures Act of 2021, issues related to international reference pricing and Part D redesign H.R. 5260 Reduced Costs and Continued Cures Act, issues related to international reference pricing and Part D redesign S. 2428 False Claims Amendments Act of 2021 H.R. 5376 Build Back Better Act, issues related to international reference pricing and Part D redesign H.R. 5801 HELP Copays Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| VICTORIA BLATTER | — |
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE New | Senator Debbie Stabeow (D-MI), left 2011, Legislative Director |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico H.R. 7527, Medical Manufacturing, Economic Development, and Sustainability Act of 2020 H.R. 6930, Manufacturing API, Drugs, and Excipients (MADE) in America Act of 2020 Proposed Rule, Guidance Related to the Foreign Tax Credit, Clarification of Foreign-Derived Intangible Income Issues related to OECD negotiations on the taxation of global income H.R.5376, "Build Back Better Act S. 4783, Territory Economic Development Tax Credit Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| JORDAN LYNN LAYSON | — |
| HELEN RHEE | — |
Copyright/Patent/Trademark CPT
S.1435 Affordable Prescriptions for Patients Act H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2428 False Claims Amendments Act of 2021 Mergers and acquisitions, no specific bill
| Lobbyist | Covered position, as disclosed |
|---|---|
| VICTORIA BLATTER | — |
| L NICOLE CURRIE | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE New | Senator Debbie Stabeow (D-MI), left 2011, Legislative Director |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.